TLR4及其抑制剂A20、SOCS1、RP105与动脉粥样硬化的关系被引量：2

下载PDF

导出

摘要动脉粥样硬化(Atherosclerosis,AS)是心脑血管疾病的病理基础,其发病机制备受关注,但至今尚未阐明。近些年来,研究TLR4(Toll like receptor 4)信号通路在AS中的作用机制成为心血管领域中的热点。本文就TLR4及其抑制剂A20、SOCS1、RP105与AS之间关系作一综述。

作者王辉波杨俊

机构地区三峡大学心血管病研究所三峡大学第一临床医学院心内科

出处《海南医学》 CAS 2015年第13期1938-1940,共3页 Hainan Medical Journal

基金国家自然科学基金(编号:81170133 81200088 81470387) 宜昌市科技研究与开发项目(编号:A12301-01) 湖北省首届医学领军人才基金

关键词 TOLL样受体4 锌指蛋白A20 SOCS1 RP105 动脉粥样硬化

分类号 R543.5 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献23

1Jia SJ, Niu PP, Cong JZ, et al. TLR4 signaling: A potential therapeu-tic target in ischemic coronary artery disease [J]. International Im-munopharmacology, 2014,23(1): 54-59.
2Park BS, Lee JO. Recognition of lipopolysaccharide pattern byTLR4 complexes [J]. Experimental & Molecular Medicine, 2013,45(12): e66.
3oe I, Read RC, Whyte MKB, et al. Toll-like receptors in healthand disease: complex questions remain [J]. The Journal of Immunol-ogy, 2003, 171(4): 1630-1635.
4杨简,杨俊.Toll样受体-4在心肌缺血再灌注损伤中作用的研究进展[J].临床心血管病杂志,2007,23(6):405-408. 被引量：4
5Zhao W, Ma G, Chen X. Lipopolysaccharide induced LOX-1 ex-pression via TLR4/MyD88/ROS activated p38MAPK-NF-.B path-way [J]. Vascul Pharmacol, 2014, 63(3): 162-172.
6Staiy HC,Chandler AB, Dinsmore RE, et al. A definition of ad-vanced types of atherosclerotic lesions and a histological classifica-tion of atherosclerosis A report from the Committee on Vascular Le-sions of the Council on Arteriosclerosis, American Heart Associa-tion [J]. Circulation, 1995, 92(5): 1355-1374.
7Edfeldt K, Swedenborg J, Hansson GK, et al. Expression of toll-likereceptors in human atherosclerotic lesions A possible pathway forplaque activation [J]. Circulation, 2002,105(10): 1158-1161.
8Jia SJ, Niu PP, Cong JZ, et al. TLR4 signaling: A potential flierapeu-tic target in ischemic coronary artery disease [J]. International Im-munopharmacology, 2014,23(1): 54-59.
9Hayashi C, Papadopoulos G, Gudino CV, et al. Protective role forTLR4 signaling in atherosclerosis progression as revealed by infec-tion with a common oral pathogen [J]. The Journal of Immunology,2012,189(7): 3681-3688.
10Dixit VM, Green S, Sarma V, et al. Tumor necrosis factor-alpha in-duction of novel gene products in human endothelial cells includinga macrophage-specific chemotaxin [J]. Journal of Biological Chem-istry, 1990, 265(5): 2973-2978.

二级参考文献24

1CHERVONSKY A V,MEDZHITOV R M,DENZIN L K,et al.Subtle conformational changes induced in major histocompatibility complex class Ⅱ molecules by binding peptides[J].Proc Natl Acad Sci U S A,1998,95:10094-10099.
2MEDZHITOV R,PRESTON-HURLBURT P,JANEWAY C A Jr.A human homologue of the Drosophila Toll protein signals activation of adaptive immunity[J].Nature,1997,388:394-397.
3TAKEDA K,KAISHO T,AKIRA S.Toll-like receptors[J].Annu Rev Immunol,2003,21:335-376.
4KAWASAKI K,AKASHI S,SHIMAZU R,et al.Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol[J].J Biol Chem,2000,275:2251-2254.
5ASEA A,REHLI M,KABINGU E,et al.Novel signal transduction pathway utilized by extracellular HSP70:role of toll-like receptor (TLR) 2 and TLR4[J].J Biol Chem,2002,277:15028-15034.
6KURT-JONES E A,POPOVA L,KWINN L,et al.Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus[J].Nat Immunol,2000,1:398-401.
7SABROE I,READ R C,WHYTE M K,et al.Toll-like receptors in health and disease:complex questions remain[J].J Immunol,2003,171:1630-1635.
8MUZIO M,BOSISIO D,POLENTARUTTI N,et al.Differential expression and regulation of toll-like receptors (TLR) in human leukocytes:selective expression of TLR3 in dendritic cells[J].J Immunol,2000,164:5998-6004.
9VIVES P M,SOMOZA N,FERNANDEZ-ALVAREZ J,et al.Evidence of expression of endotoxin receptors CD14,Toll-like receptors TLR4 and LR2 and associated molecule MD-2and of sensitivity to endotoxin(LPS) in islet beta cells[J].J Clin Exp Immunol,2003,133:208-218.
10HYAKUSHIMA N,MITSUZAWA H,NISHITANI C,et al.Interaction of soluble form of recombinant extracellular TLR4 domain with MD-2 enables lipopolysaccharide binding and attenuates TLR4-mediated signaling[J].J Immunol,2004,173:6949-6954.